Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team

Stock Information for TAT Technologies Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TAT Technologies Ltd.

Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
Plus Therapeutics Announces Private Placement Financing of up to $18 Million
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.